Although risks with estrogen therapy and breast cancer are well known, patients with a familial history or with breast cancer susceptibility genes (BRCA1 and BRCA2) do not have an additional risk with CHC [10,24,25,26,27]. Here, BRCA2 is linked to breast carcinoma.